Skip to main content
. 2014 May 19;14:340. doi: 10.1186/1471-2407-14-340

Figure 2.

Figure 2

FCGR2A response rates in patients with KRAS wild-type tumors. There was no significant difference in response rates when cetuximab was added to Nordic FLOX in the different FCGR2A subgroups (interaction P = 0.27).